The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10364 malaria professionals are enjoying the free benefits of MalariaWorld today

recurrence

NOT Open Access | Novel insights into Plasmodium vivax therapeutic failure: CYP2D6 activity and time of exposure to malaria modulate the risk of recurrence

March 9, 2020 - 14:21 -- NOT Open Access
Author(s): 
Silvino ACR, Kano FS, Costa MA, Fontes CJF, Soares IS, Brito CFA, Carvalho LH, Sousa TN
Reference: 
Antimicrob Agents Chemother. 2020 Mar 2. pii: AAC.02056-19

Plasmodium vivax relapse is one of the major causes of sustained global malaria transmission. Primaquine (PQ) is the only commercial drug available to prevent relapses, and its efficacy is dependent on metabolic activation by cytochrome P450 2D6 (CYP2D6). Impaired CYP2D6 function, caused by allelic polymorphisms, leads to the therapeutic failure of PQ as a radical cure for P. vivax malaria.

The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis

October 15, 2019 - 15:36 -- Open Access
Author(s): 
Robert J. Commons, Julie A. Simpson, Ric N. Price, et al.
Reference: 
PLoS Med 16(10): e1002928

Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax.

Medical Condition: 
Subscribe to RSS - recurrence